Top 10 Clinical Trials to Follow in Early 2026

Intellia Therapeutics has emerged as a key player in the biopharmaceutical sector, particularly in the realm of gene editing technology known as CRISPR. Despite facing significant challenges, including financial strains and setbacks in clinical trials, the company holds potential for future success. As it braces for 2026, a notable clinical trial awaits that could redefine treatment for hereditary angioedema (HAE).

Intellia Therapeutics: A Brief Overview

Founded on the groundbreaking CRISPR technology, Intellia has invested over $2 billion since its inception. However, the company has encountered hurdles, including staff layoffs and a suspension of key programs, which have heavily impacted its share price.

Upcoming Phase 3 Clinical Trial

In the first half of 2026, Intellia is set to release results from a Phase 3 trial for a therapy called lonvo-z. This treatment aims to tackle hereditary angioedema, a rare condition known for causing painful swelling attacks.

Potential Benefits of Lonvo-z

• Lonvo-z may act as a “functional cure,” reducing reliance on frequent injections and medications.
• The therapy has shown promise in reducing swelling attacks effectively.
• Unlike another program, nex-z, lonvo-z has not exhibited liver-related complications in patients.

Market Outlook and Expert Opinions

Analysts, including Jonathan Miller from Evercore ISI, express optimism about lonvo-z. They indicate a “good probability of success” in the upcoming trial. Should the therapy gain approval, it may achieve a “competitive commercial profile.”

Technical differences between lonvo-z and nex-z are key to understanding their distinct effects. Lonvo-z targets different genes and utilizes varying RNA guidance techniques, which may result in favorable outcomes for younger and healthier HAE patients.

Challenges Ahead for Intellia

Despite the optimism surrounding lonvo-z, Intellia faces a competitive landscape. There are already multiple effective treatments for HAE on the market. To carve its niche, Intellia must demonstrate the exceptional efficacy and safety of lonvo-z compared to existing therapies.

Miller projects that, in peak years, sales for lonvo-z could potentially reach up to $500 million. This forecast reflects the current dynamics in the gene therapy market and the challenges associated with launching new treatments.

As Intellia anticipates the outcome of the Phase 3 trial in early 2026, the industry will closely monitor its progress. The results could signify a pivotal moment not just for Intellia but for the treatment landscape of hereditary angioedema.